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Abstract: Treatment of the known half-sandwich complexes of the type [(η6-C6H6)RuCl2(P(OR)3)]
(R = Me or Ph) with SnCl2 yielded three new half-sandwich ruthenium complexes (C1–C3):
[(η6-C6H6)RuCl(SnCl3)(P(OMe)3)] (C1), [(η6-C6H6)RuCl(SnCl3)(P(OPh)3)] (C2) and the bis-stannyl
complex [(η6-C6H6)Ru(SnCl3)2(P(OMe)3)] (C3) by facile insertion of SnCl2 into the Ru–Cl bonds.
Treatment of the known complexes [(η6-C6H6)RuCl(SnCl3)(PPh3)] and [(η6-C6H6)RuCl2(PPh3)]
with 4-dimethylaminopyridine (DAMP) and ammonium tetrafluoroborate afforded the complex
salts: [(η6-C6H6)Ru(SnCl3)(PPh3)(DAMP)]+BF4− (C4) and [(η6-C6H6)RuCl(PPh3)(DAMP)]+BF4− (C5)
respectively. Complexes C1–C5 have been fully characterized by spectroscopic means (IR, UV–vis,
multinuclear NMR, ESI–MS) and their thermal behaviour elucidated by thermal gravimetric analysis
(TGA). Structural characterization by single crystal X-ray crystallography of the novel complex
C2 and [(η6-C6H6)RuCl2(P(OPh)3)], the latter having escaped elucidation by this method, is also
reported. Finally, the cytotoxicity of the complexes was determined on the A2780 (human ovarian
cancer), A2780cisR (human ovarian cis-platin-resistant cancer), and the HEK293 (human embryonic
kidney) cell lines and discussed, and an attempt is made to elucidate the effect of the stannyl ligand
on cytotoxicity.
Keywords: bioorganometallic chemistry; metal-based drugs; phosphorus ligands; ruthenium;
half-sandwich complexes; tin dichloride insertion
1. Introduction
Since the discovery of the anti-cancer properties of cis-platin, [cis-PtCl2(NH3)2] and related
complexes [1–4], research directed towards the development of new metal-containing anticancer
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drugs has made staggering advances [5–15]. Metals other than platinum are worth investigating in
the search for new classes of metallodrugs with high efficacy and fewer side effects. The ongoing
search for new metallodrugs has led to the discovery of several ruthenium-based drugs: NAMI-A and
KP1019, both of which have completed phase I clinical trials, as well as RAPTA-C (Chart 1) [16–23].
In addition, ruthenium(II)-arene complexes are also considered promising drug candidates, owing
to their demonstrated low toxicity and high antitumor activity [18–30]. The bioavailability of these
compounds is controlled by the arene moieties facilitating the outreach in the intracellular region given
their hydrophobic nature [29].
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Ru(II)-arene phosphine complexes [31,32]. A stable phosphine complex, reported in the 1970s 
[(η6-C6H6)RuCl2(PPh3)] [31,32], which is obtained in high yields as a product via a reaction of the 
afore-mentioned ruthenium dimer with triphenylphosphine. Similarly the phosphite derivatives 
[(η6-C6H6)RuCl2(P(OMe)3)] and [(η6-C6H6)RuCl2(P(OPh)3)] are afforded by reaction of 
[(η6-C6H6)Ru(μ-Cl)Cl]2 with trimethyl phosphite and triphenyl phosphite in an analogous fashion 
[32–34]. Surprisingly, despite the fact that these easily accessible phosphite complexes have been 
known since the early 1970s, they have not undergone rigorous in vitro cytotoxic testing with respect 
to cancer cell lines. This encouraged us to prepare and evaluate their cytotoxic activity. Moreover, to 
the best of our knowledge, the complex [(η6-C6H6)RuCl2(P(OPh)3)] has also not been structurally 
characterised by single crystal X-ray diffraction analysis, which prompted us to carry out such an 
investigation, and this is also reported herein. 
The reaction of half-sandwich ruthenium(II) arene complexes [(η6-C6H6)RuCl2(PR3)] (R = aryl or 
O-Aryl, O-alkyl) with SnCl2 is also known to yield a Ru(II) complex exhibiting a strong covalent 
Ru-Sn bond via facile insertion of the SnCl2 moiety into the Ru–Cl bond [35,36]. While the reaction of 
SnX2 (X = halide) with other metals, such as palladium and platinum, has been extensively studied 
[37,38], the analogous reaction with ruthenium derivatives has received far less attention. The 
addition of trichlorostannyl ligands to the coordination sphere of the ruthenium centre is known to 
enhance the anticancer properties of the complexes from earlier investigations [39], possibly due to 
the enhanced σ-donor properties of the ligand, which might facilitate and promote the binding of 
the agent to potential biomolecular targets. Although there is known to be an increase in 
cytotoxicity, only a few examples of this class, i.e., those bearing stannyl groups, have been tested. 
In this work we report the synthesis and characterisation of a series of complexes of formula 
[(η6-C6H6)RuX(SnCl3)(P(OR)3)] (X = Cl, SnCl3 and R = Me, Ph), and some cationic derivatives 
[(η6-C6H6)RuX(PPh3)(DAMP)]BF4 (X = SnCl3, Cl), with a view of attempting to delineate the effect of 
a trichlorostannyl group on cytotoxicity against several cancer cell-lines. Hence, the cytotoxicity of 
these new complexes against A2780 and A2780cisR (cis-platin resistant) human ovarian carcinoma 
cells and non-cancerous HEK293 embryonic kidney cells are reported, along with the known 
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A particularly interesting class of compounds in this regard are the easily accessible half-sandwich
ruthenium(II) complexes of the type [(η6-C6H6)RuCl2(PR3)] (R = Aryl, O-alky, O-Aryl). Facile reaction
of the arene ruthenium dimer [(η6-C6H6)Ru(µ-Cl)Cl]2 with strong σ-donor ligands, such as phosphines
or phosphites, promote the cleavage of the Ru(II) dimer yielding half-sandwich Ru(II)-arene phosphine
complexes [31,32]. A stable phosphine complex, reported in the 1970s [(η6-C6H6)RuCl2(PPh3)] [31,32],
which is obtained in high yields as a product via a reaction of the afore-mentioned ruthenium
dimer with triphenylphosphine. Similarly the phosphite derivatives [(η6-C6H6)RuCl2(P(OMe)3)]
and [(η6-C6H6)RuCl2(P(OPh)3)] are afforded by reaction of [(η6-C6H6)Ru(µ-Cl)Cl]2 with trimethyl
phosphite and triphenyl phosphite in an analogous fashion [32–34]. Surprisingly, despite the fact
that these easily accessible phosphite complexes have been known since the early 1970s, they have
not undergone rigorous in vitro cytotoxic testing with respect to cancer cell lines. This encouraged
us to prepare and evaluate their cytotoxic activity. Moreover, to the best of our knowledge, the
complex [(η6-C6H6)RuCl2(P(OPh)3)] has also not been structurally characterised by single crystal
X-ray diffraction analysis, which prompted us to carry out such an investigation, and this is also
reported herein.
The reaction of half-sandwich ruthenium(II) arene complexes [(η6-C6H6)RuCl2(PR3)] (R = aryl or
O-Aryl, O-alkyl) with SnCl2 is also known to yield a Ru(II) complex exhibiting a strong covalent Ru-Sn
bond via facile insertion of the SnCl2 moiety into the Ru–Cl bond [35,36]. While the reaction of SnX2
(X = halide) with other metals, such as palladium and platinum, has been extensively studied [37,38],
the analogous reaction with ruthenium derivatives has received far less attention. The addition of
trichlorostannyl ligands to the coordination sphere of the ruthenium centre is known to enhance the
anticancer properties of the complexes from earlier investigations [39], possibly due to the enhanced
σ-donor properties of the ligand, which might facilitate and promote the binding of the agent to
potential biomolecular targets. Although there is known to be an increase in cytotoxicity, only a few
examples of this class, i.e., those bearing stannyl groups, have been tested.
In this work we report the synthesis and characterisation of a series of complexes of formula
[(η6-C6H6)RuX(SnCl3)(P(OR)3)] (X = Cl, SnCl3 and R = Me, Ph), and some cationic derivatives
[(η6-C6H6)RuX(PPh3)(DAMP)]BF4 (X = SnCl3, Cl), with a view of attempting to delineate the effect of
a trichlorostannyl group on cytotoxicity against several cancer cell-lines. Hence, the cytotoxicity of
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these new complexes against A2780 and A2780cisR (cis-platin resistant) human ovarian carcinoma
cells and non-cancerous HEK293 embryonic kidney cells are reported, along with the known
complexes [(η6-C6H6)RuCl2(PPh3)], [(η6-C6H6)RuCl2(P(OPh)3)] and [(η6-C6H6)RuCl(SnCl3)(PPh3)],
was determined.
2. Results and Discussion
2.1. Synthesis of the Complexes
The reaction of the known complexes [(η6-C6H6)RuCl2(P(OX)3)] (X = Me, Ph) with
1.1 equivalents of anhydrous SnCl2 in dichloromethane under reflux affords the complexes
[(η6-C6H6)RuCl(SnCl3)(P(OX)3)] (X = Me C1; X = Ph, C2), which were isolated in 64% and 69%
yield (Scheme 1), respectively. The reaction of [(η6-C6H6)Ru(SnCl3)Cl(P(OMe)3)] with a large excess
of SnCl2 in refluxing dichloromethane for 24 h affords the bis-(trichlorostannyl) complex C3 in 34%
yield. The latter complex can also be prepared directly starting from [(η6-C6H6)RuCl2(P(OMe)3)] with
a 20-fold molar excess of SnCl2 in dichloromethane affording similar yields. Complex C3, owing to the
presence of an additional SnCl3 moiety is less solubility in dichlormethane or chloroform than C1 and
C2, which are highly soluble in these solvents.
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2.2. Spectroscopic Characterisation 
Complexes C1–C3 all exhibit an upfield shifted resonance signal, for the arene protons 
associated with the η6-coordinated ring, in the 1H NMR spectra: δ = 6.31 ppm (C1 and C3), 5.82 (C2). 
Scheme 1. Synthesis of mono(trichlorostannyl) complexes C1 and C2 and di(trichlorostannyl) complex C3.
Reaction of [(η6-C6H6)RuClX(PPh3)] (X = Cl, X= SnCl3) with 1.1 equivalents of
4-dimethylaminopyridine (DMAP) and 1.1 equivalent of ammonium tetrafluoroborate in refluxing
methanol affords the complex ionic salts C4 and C5 (Scheme 2), both of which are fully characterised
by spectroscopic and analytical methods. All complexes C1–C5 exhibit reasonable thermal stability as
evidenced by decomposition temperatures in excess of 100 ◦C.
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2.2. Spectroscopic Characterisation
Complexes C1–C3 all exhibit an upfield shifted resonance signal, for the arene protons associated
with the η6-coordinated ring, in the 1H NMR spectra: δ = 6.31 ppm (C1 and C3), 5.82 (C2). In complexes
C1 and C3, a doublet is observed in the 1H NMR spectrum corresponding to the P(OMe)3 groups due
to coupling to the phosphorus atom: 3J(H,P): C1: 12.0 Hz, C3: 12.3 Hz.
Complexes C1–C3 exhibit singlet resonance signals in their 31P{1H} NMR spectra: (C1: δ = 131.2,
C2: δ = 122.1, C3: δ = 136.5 ppm). Notaby, the presence of both 119Sn and 117Sn satellites, flanking
the main resonance signals in all three complexes (C1–C3) are visible in these spectra due to
2J(Sn,P) coupling. The presence of the Sn satellites in the 31P{1H} NMR spectra suggest, that in
DMSO(dimethyl sulfoxide), the complexes are stable and dynamic SnCl3− exchange is unlikely to
occur. The formation, in DMSO solutions, of [(η6-C6H6)Ru(SnCl3)(DMSO)(PR3)]+Cl− can be ruled
out for the mono-insertion products C1 and C2 over the time periods of the NMR measurements
in DMSO-d6 (12 h). The cationic complexes C4 and C5 exibit dramatically shielded chemical shift
positions in their respective 31P{1H} NMR spectra (C4: δ = 26.7, C5: δ = 36.0 ppm) compared with
the neutral complexes C1–C3, owing to their cationic nature. Unfortunately 119Sn NMR spectroscopy
could not be carried out on the tin compounds due to the lack of a suitable probe in our laboratories.
The 31P{1H} NMR spectrum of complex C1 is shown in Figure 1. Both 119Sn and 117Sn satellites
are visible, along with rotational side-bands on the main signal, the latter of which is typical in solution
31P NMR spectra.
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obtain information on their thermal behaviour and stability. In all cases the complexes are thermally 
robust with the first onset of mass loss occurring well in excess of 100 °C: (C1: 122 °C, C2: 186 °C, C3: 
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temperature) determinations. An exact assignment of the mode of decomposition, i.e., according to 
which fragments are lost at which temperature was undertaken, and in all cases one decomposition 
step can be tentatively traced to the loss of the η6 coordinated ring. Figure 2 shows the TGA trace of 
complex C1. The approximately 12% mass loss can be roughly correlated to the loss of the arene ring. 
Figure 1. The 31P NMR spectrum of complex C1 in which the main resonance signal is flanked with
117Sn (inner) and 119Sn (outer) satellites.
Inspection of the experimental solution UV–vis spectra of the complexes C1–C3 reveal that, for
the bis-trichlorostannyl complex C3, a much higher wavelength of absorption (λ = 459 nm) is observed
compared to C1: λ = 348 and C2: λ = 351 nm, indicating pertubation in the electronic situation upon bis
SnCl2-insertion. This is most likely due to the enhanced σ-donor capacity of SnCl3− vs. Cl−. For the
ionic complex the UV–vis spectra reveal absorptions at λ = 364 (C4) and λ = 335 nm (C5), comparable
to that of C1 and C2. All complexes were also subjected to a TGA analysis to obtain information on
their thermal behaviour and stability. In all cases the complexes are thermally robust with the first onset
of mass loss occurring well in excess of 100 ◦C: (C1: 122 ◦C, C2: 186 ◦C, C3: 223 ◦C, C4: 184 ◦C, and
C5: 190 ◦C), which is in accord with the melting point (decomposition temperature) determinations.
An exact assignment of the mode of decomposition, i.e., according to which fragments are lost at which
temperature was undertaken, and in all cases one decomposition step can be tentatively traced to the
loss of the η6 coordinated ring. Figure 2 shows the TGA trace of complex C1. The approximately 12%
mass loss can be roughly correlated to the loss of the arene ring.
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Figure 3. ORTEP view of (C2) with atom-labelling scheme and thermal ellipsoids drawn at the 50% 
probability level. Selected bond distances (Å) and bond angles (°): Ru(1)–Sn(1) = 2.5686(5), Ru(1)–
Cl(1) = 2.3919(10), Ru(1)–P(1) = 2.2.242(12). P(1)–Ru(1)–Cl(2) = 90.90(2), P(1)–Ru(1)–Cl(1) = 81.72(2), 
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Figure 2. TGA trace of complex C1 with the onset of decomposition occuring at 121.51 ◦C.
2.3. X-ray Crystallography
Single crystals of complex C2 and [(η6-C6H6)RuCl2(P(OPh)3)] were obtained and single crystal
X-ray diffraction studies were undertaken and their structures are shown in Figures 3 and 4,
respectively with selected metric parameters provide in the figure captions (other bond angles and
lengths are available in the supporting information). It is somewhat surprising that the complex
[(η6-C6H6)RuCl2(P(OPh)3)] has eluded structural characterisation by X-ray diffraction, despite being
reported in the 1970s.
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Figure 3. ORTEP view of (C2) with atom-labelling scheme and thermal ellipsoids
drawn at the 50% probability level. Selected bond distances (Å) and bond angles (◦):
Ru(1)–Sn(1) = 2.5686(5), Ru(1)–Cl(1) = 2.3919(10), Ru(1)–P(1) = 2.2.242(12). P(1)–Ru(1)–Cl(2) = 90.90(2),
P(1)–Ru(1)–Cl(1) = 81.72(2), and Cl(2)–Ru(1)–Cl(1) = 87.49(2).
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Figure 4. ORTEP view of [(η6-C6H6)RuCl2P(OPh)3] with atom-labelling scheme and
thermal ellipsoids drawn at the 50% probability level. Selected bond distances (Å)
and bond angles (◦): C(1)–Ru(1) = 2.191(5), C(2)–Ru(1) = 2.254(5), C(3)–Ru(1) = 2.175(5),
C(4)–Ru(1) = 2.246(5), C(5)–Ru(1) = 2.245(5), C(6)–Ru(1) = 2.249(5), C(1–6)–Ru(1)–P(1) = 117.49(18),
P(1)–Ru(1)–Cl(1) = 85.71(4), P(1)–Ru(1)–Sn(1) = 86.84(3), and Cl(1)–Ru(1)–Sn(1) = 83.67(3).
Both complexes exhibit the typical piano-stool geometry with the metal centre being coordinated
by the arene in η6 fashion. Complex C2 exhibits a Ru–Sn bond length of 2.5686(5) Å,
which is comparable to known similar complexes featuring Ru–Sn single bonds, for example:
[(η6-C6H6)RuCl(SnCl3)(PPh)3]: 2.5977(14) Å and [(η6-p-cymene)RuCl(SnCl3)(PPh)3]: 2.5830(9) Å (see
the X-ray structures in Ref. [35]) respectively. Previous structural investigations into complexes of the
type [(η6-C6H6)RuCl2(PR3)] (R = alkyl, aryl) are ubiquitous, but only three examples of previously
structurally-characterised complexes of the type [(η6-C6H6)RuCl2(P(OR)3)] (i.e., arene phosphite
complexes) exist [40–42] making the structural elucidation of both C2 and [(η6-C6H6)RuCl2P(OPh)3]
of some interest.
2.4. Cytotoxicity Studies
The antiproliferative activity of the neutral complexes C1–C3, cationic complexes C4 and
C5 and the three known compounds [(η6-C6H6)RuCl2(PPh3)], [(η6-C6H6)RuCl2(P(OPh)3)], and
[(η6-C6H6)RuCl(SnCl3)(PPh3)] were investigated in vitro against human ovarian cancer cells A2780
and the A2780cisR variant with aquired cis-platin resistance, as well as against non-cancerous human
embryonic kidney (HEK293) cells (Table 1). The cytotoxicity of the latter three complexes has not
been reported previously and are shown together with cis-platin for comparison (Table 2). IC50 values
of the compounds were determined after exposure of the cells to the compounds for 72 h using the
MTT assay.
Complexes C1 and C3 with trimethylphosphite ligands did not induce cytotoxicity even
at concentrations as high as 500 µM and 200 µM, respectively, whereas all complexes with
triphenylphosphite or triphenylphosphine ligands exhibit considerable cytotoxicity in A2780,
A2780cisR and HEK293 cells. This is somewhat surprising as the presence of the SnCl3 moiety
would have been expected to enhance the cytotoxic effect of the complex (see above). In case of
complex C3, this may be due to its rather low solubility due to the presence of two trichlorostannyl
groups attached to the Ru centre. Notably, the cationic complexes C4 and C5 display IC50 values in
the low micromolar concentration range and, compared to cis-platin, showed even high efficacy in
A2780cisR cells. Whereas complex C5 bearing a chloride ligand showed similar activity in all three cell
lines, complex C4 with the chlorine replaced by the SnCl3 moiety, showed slight cancer cell selectivity.
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This phenomenon was not observed for [(η6-C6H6)RuCl2(PPh3)] and [(η6-C6H6)RuCl(SnCl3)(PPh3)],
where the tin congener induced generally a two-fold higher cytotoxicity, but did not contribute to cancer
cell selectivity. In contrast, the complexes with triphenylphosphite ligands [(η6-C6H6)RuCl2(P(OPh)3)]
and its tin congener C2 show the opposite behaviour with C2 being >20-fold less potent than
[(η6-C6H6)RuCl2(P(OPh)3)].
Overall looking at these results in totality and attempting to delineate the effect of the
trichlorostannyl group on cytotoxicity is not straightforward as obviously solubility plays a key
role which might offset the otherwise enhanced cytotoxic activity. Comparison of ionic complexes C4
and C5 which have similar solubilities clearly do demonstrate, however, on average, an increase in
cytotxicity in the presence of SnCl3− vs. Cl− (except for HEK293). This does suggest that the SnCl3−
ligand is useful in this regard, but complex C3, for example, bearing two SnCl3− ligands exhibits very
low activity which is driven by its insolubility, thereby potentially offsetting any enhanced efficacy in
its cytotoxic effects. We are currently preparing more related complexes to attempt to delineate these
effects more closely.
Table 1. In vitro cytotoxicity of complexes against selected tumour cell lines after 72 h drug exposure.
Compound IC50 (µM)
a
A2780 A2780cisR HEK293
C1 >500 >500 >500
C2 51.5 ± 0.1 51.5 ± 0.1 25.0 ± 6.2
C3 >200 >200 >200
C4 3.4 ± 0.4 4.1 ± 0.9 14.2 ± 4.9
C5 6.5 ± 0.9 7.1 ± 1.6 3.2 ± 0.3
[(η6-C6H6)RuCl2(PPh3)] 30.5 ± 0.7 27.0 ± 5.6 27.8 ± 6.8
[(η6-C6H6)RuCl2(P(OPh)3)] 2.3 ± 0.02 3.2 ± 0.4 1.0 ± 0.5
[(η6-C6H6)RuCl(SnCl3)(PPh3)] 12.4 ± 0.4 12.5 ± 3.0 4.9 ± 0.1
cis-platin 1.1 ± 0.4 14.4 ± 2.1 10.6 ± 1.4
a IC50 values (µM) are presented as mean ±SD of two or more independent experiments. The sign (>) indicates that
IC50 value was not obtained up to given concentration.
3. Experimental
3.1. General Procedures
All manipulations were performed in air as the Ru(II) complexes are stable towards air and
moisture. All starting materials and solvents were obtained commercially (Strem, Sigma-Aldrich,
Zwijndrecht, Netherlands) and used as received. [(η6-C6H6)RuCl2(PPh3)], [(η6-C6H6)RuCl2(P(OPh)3)],
and [(η6-C6H6)RuCl(SnCl3)(PPh3)] were prepared according to published procedures [31–36], and
the complexes obtained were characterised by 1H and 31P NMR spectroscopy and checked against
literature data. NMR spectra were recorded on a Bruker Ultrashield 300 (Karlsruhe, Germany),
IR spectra on a Shimadzu MIRacle IR (ATR, Kyoto, Japan), UV–vis on a Shimadzu UV 3600 (Kyoto,
Japan), and TGA spectra were recorded on a TGA Q-500 (Maastricht, Netherlands) at the University of
Maastricht Brightlands Campus, Netherlands. Electrospray (ESI) mass spectrometry experiments were
conducted on BRUKER—Ion Trap MS (Karlsruhe, Germany) in positive mode (+) at the University
of Neuchâtel, Switzerland. The following abbreviations apply to the intensity of peaks found within
the spectra (IR): v: very strong; s: strong; m: medium; and w: weak. For NMR peaks obtained for
the non-deuterated residue in the deuterated solvent were used as the internal reference points for
the spectra (reference peak: DMSO-d6, 1H 2.49 ppm; 13C 39.5 ppm, CHCl3-d1, 1H 7.26 ppm; and
13C 77.2 ppm). All signals have been recorded using their appropriate chemical shift (δ in ppm),
multiplicity, integral ratio, and coupling constants [Hz]. The following abbreviations apply to the
signal multiplicity of peaks within spectra: s = singlet, d = doublet, t = triplet, and m = multiplet.
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3.2. Synthesis of the Complexes
3.2.1. Synthesis of [(η6-C6H6)RuCl(SnCl3)(P(OMe)3)] (C1)
[(η6-C6H6)RuCl2(P(OMe)3)] (0.500 g, 1.340 mmol) and 1.1 equivalents of anhydrous SnCl2 (0.279 g,
1.474 mmol) were dissolved in 30 mL of dichloromethane and heated under reflux for 3 h. The reaction
mixture was cooled to room temperature and filtered to remove excess SnCl2.The bright orange
solution was evaporated to dryness in vacuo and afforded a scarlet powder which was subsequently
washed with n-hexane (3 × 10 mL) and dried under reduced pressure. Yield 64%. m.p.: 103 ◦C dec.
FTIR: v (cm−1): 3075 (w), 2959 (w), 2843 (vw), 1458 (w), 1439 (m), 1260 (m), 1177 (w), 1153 (vw),
1063 (m), 1005 (vs), 922 (w), 866 (w), 791 (vs), 752 (s), 706 (m), 662 (m), 608 (w), 542 (w). 1H NMR:
(300.1 MHz, DMSO-d6, δ, ppm): 6.31 (s, 6H, C6H6), 3.82 (d, 3J(H,P) = 12.0 Hz, 9H, P(OMe)3). 13C NMR:
(75.5 MHz, DMSO-d6, δ, ppm): 92.4 (d, 2J(C,P) = 3.9 Hz, C6H6), 54.7 (d, 2J(C,P) = 6.2 Hz, P(OMe)3).
31P NMR: (121.5 MHz, DMSO-d6, δ, ppm): 131.2 (s, 2J(119Sn,P) = 1004.90 Hz; 2J(117Sn,P) = 949.80 Hz).
TGA: (Weight % decrease): 121.51–178.15 ◦C (4.53%), 178.15–232.72 ◦C (2.23%), 232.72–245.63 ◦C
(3.80%), 245.63–321.43 ◦C (11.72%) 321.43–351.83 ◦C (15.77%). UV–vis (nm)/dichloromethane: 347.5,
451.0. EI-MS (CH3CN): m/z 339.0 [M − SnCl3]+, 353.4, 381.4, 397.3, 414.9, 426.0, 463.0, 481.0, 522.0,
537.0, 554.6, 582.7 [M + Na]+ (other higher mass unassignable fragments present).
3.2.2. Synthesis of [(η6-C6H6)RuCl(SnCl3)(P(OPh)3)] (C2)
Complex (C2) was synthesized in an analogous fashion as for (C1) starting from
[(η6-C6H6)RuCl2(P(OPh)3)]: (0.500 g, 0.892 mmol) and SnCl2 (0.186 g, 0.981 mmol). Bright-orange
crystals. Yield 69%. m.p.: 197 ◦C dec. FTIR: v (cm−1): 3075 (vw), 296 3(vw), 1583 (m), 1481 (s), 1437 (w),
1260 (w), 1206 (m), 1182 (s), 1173 (s), 1152 (s), 1022 (m), 945 (s), 922 (s), 908 (s), 891 (s), 822 (vs), 800 (m),
766 (vs), 688 (s), 601 (m). 1H NMR: (300.1 MHz, DMSO-d6, δ, ppm): 7.50 (d, 3J(H,H) = 7.4 Hz, 6H,
P(OPh3)), 7.35 (d, 3J(H,H) = 7.4 Hz, 3H, P(OPh)3), 7.34 (br s, 6H, P(OPh)3), 5.84 (br s, 6H, C6H6),
13C NMR: (75.5 MHz, DMSO-d6, δ, ppm): 151.0 (d, 1J(C,P)= 10.8 Hz, C1, P(OPh)3), 130.5 (s, C2,6,
P(OPh)3), 126.4 (s, C4, P(OPh)3), 121.9 (d, xJ(C,P) = 4.2 Hz, C3,5, P(OPh)3), 92.9 (d, 2J(C,P) = 3.8 Hz, C6H6),
31P NMR: (300.1 MHz, DMSO-d6, δ, ppm): 122.1 (s, 3J(119Sn,P) = 989.0 Hz, 2J(117Sn,P) = 946.6 Hz).
TGA: (Weight % decrease): 185.99–202.83 ◦C (4.52%), 202.83–347.70 ◦C (18.50%), 347.70–393.60 ◦C
(30.06%). UV–vis (nm)/dichloromethane: 351.1, 453.0. ESI–MS (CH3CN/MeOH): m/z 123.2, 353.4,
381.4, 449.3, 516.5, 599.1, 683.4, 711.0, 739.0, 767.7 [M + Na]+ (other higher mass fragments present).
3.2.3. Synthesis of [(η6-C6H6)Ru(SnCl3)2(P(OMe)3)] (C3)
The complex C1 was weighed into a flask (0.900 g, 1.200 mmol) along with a twenty-fold molar
excess of SnCl2 (4.560 g, 24.000 mmol) in dichloromethane (100 mL) and refluxed for 20 h. During
this time the reaction turned a lemon-yellow colour. The reaction solution was filtered to remove
unreacted SnCl2 and the solvent of the filtrate removed in vacuo affording a pineapple-yellow waxy
solid, which was washed with Et2O (3 × 10 mL) and the washings discarded. The compound can
also be prepared directly from [η6-(C6H6)RuCl2(P(OMe)3)] with addition of a large excess of SnCl2
(20 molar equiv.) in dichloromethane with reflux for 24 h and isolation as describe above. Yield 34%.
m.p.: 146 ◦C dec. Conductivity (DMSO): (µS·cm−1, 21 ◦C, 0.5 mg·mL−1): 0.2. FTIR: v (cm−1): 3078
(vw), 2961 (vw), 1441 (w), 1260 (m), 1173 (w), 1088 (m), 1009 (vs), 922 (w), 864 (w), 787 (vs), 733 (s),
704 (m), 662 (w), 648 (w), 608 (vw), 561 (w). 1H NMR: (300.1 MHz, DMSO-d6, δ, ppm): 6.31 (br s, 6H,
C6H6), 3.72 (d, 3J(H,P) = 12.3 Hz, 9H, P(OMe)3), 13C NMR: (75.5 MHz, DMSO-d6, δ, ppm): 94.0 (d,
2J(C,P) = 4.1 Hz, C6H6), 54.5 (d, 2J(C,P) = 6.6 Hz, P(OMe)3), 31P NMR: (121.5 MHz, DMSO-d6, δ, ppm):
136.5 (s, 2J(119Sn,P) = 741.7 Hz; 2J(117Sn,P) = 722.1 Hz). TGA: (Weight % decrease): 223.14–273.12 ◦C
(12.70%), 273.12–317.27 ◦C (2.02%), 317.27–336.42 ◦C (11.56%), 336.42–394.73 ◦C (31.77%). UV–vis:
(nm)/dichloromethane: 459. ESI–MS (CH3CN/MeOH): m/z 477.3, 541.2, 610.2, 615.2, 631.1, 684.2,
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689.1, 698.6, 705.1, 718.5, 747.0, 758.2, 779.1 [M + Na]+ (other higher mass unassignable fragments
also present).
3.2.4. Synthesis of [(η6-C6H6)Ru(SnCl3)(PPh3)(DMAP)]+BF4− (C4)
[(η6-C6H6)RuCl(SnCl3)(PPh3)] (0.30 g, 0.60 mmol) in 25 mL of methanol was stirred for ca. 5 min.
1.1 molar equivalents of 4-dimethylaminopyridine (DMAP) (0.060 g, 0.66 mmol) was added to the
mixture and stirred for 30 min and 1.1 equivalent of ammonium tetrafluoroborate (0.05 g, 0.66 mmol)
was added to the solution and the mixture heated at reflux overnight. The distinct orange solution was
evaporated to dryness and afforded a dark red powder, which was subsequently washed with n-hexane
and dried under reduced pressure. Yield 96%. m.p.: 119 ◦C dec. FTIR: v (cm−1): 3479 (w), 3317 (w),
3055 (w), 2960 (w), 2823 (w), 1647 (m), 1616 (w), 1560 (m), 1480 (w), 1433 (m), 1419 (m), 1404 (m),
1250 (m), 1217 (m), 1186 (w), 1087 (s), 1060 (s), 1026 (vs), 997 (m), 941 (w), 819 (m), 798 (s), 748 (s),
723 (m), 696 (s), 659 (m). 1H NMR: (300.1 MHz, CDCl3, δ, ppm): 8.02 (br s, 2H, C5H4N(N(CH3)2))
7.77-7.38 (m, 15H, PPh3), 6.76 (br s, 2H, C5H4N(N(CH3)2), 5.40 (s, 6H, C6H6), 3.25 (s, 6H, N(CH3)2). 13C
NMR: (75.5 MHz, CDCl3, δ, ppm): (low field signals expected for DMAP not visible, nor C1 of PPh3),
134.2 (d, xJ(C,P) = 10.7 Hz, C2,6, PPh3) 131.0 (br s, C4, PPh3), 128.2 (d, xJ(C,P) = 9.6 Hz, C3,5, PPh3),
106.9 (s, C5H4N(N(CH3)2), 89.2 (d, 2J(C,P) = 3.6 Hz, C6H6), 40.3 (s, N(CH3)2). 31P NMR: (121.5 MHz,
CDCl3, δ, ppm): 26.7 (s). TGA: (Weight % decrease): 183.46–242.84 ◦C (5.7%), 242.84–277.79 ◦C (4.77%),
277.79–337.59 ◦C (26.75%), 337.59–404.13 ◦C (18.85%). UV–vis: (nm)/dichloromethane: 364.5. ESI–MS
(CH3CN): m/z 123.2 [DMAP + H]+, 401.1, 479.0, 599.1, 635.0, 738.0, 785.0 (other unassignable higher
mass fragments also present).
3.2.5. Synthesis of [(η6-C6H6)RuCl(PPh3)(DMAP)]+BF4− (C5)
Complex (C5) was synthesized in an analogous fashion as (C4), except [(η6-C6H6)RuCl2(PPh3)]
was used as starting material. The work up and isolation procedure is analogous. Yield 24%. m.p.:
176 ◦C dec. FTIR: v (cm−1): 2898 (w), 2983 (w), 1622 (m), 1614 (m), 1588 (m), 1537 (m), 1481 (m),
1435 (m), 1406 (m), 1386 (m), 1230 (m), 1089 (s), 1055 (vs), 1018 (vs), 999 (s), 808 (m), 748 (s), 694 (vs).
1H NMR: (300.1 MHz, CDCl3, δ, ppm): 8.21 (d, 3J(H,H) = 6.1 Hz, C5H4N(N(CH3)2)), 7.38–7.73 (m,
15H, PPh3), 6.26 (d, 3J(H,H) = 6.21 Hz, C5H4N(N(CH3)2)), 5.76 (s, 6H, C6H6), 2.94 (s, 6H, N(CH3)2).
13C NMR: (75.5 MHz, CDCl3, δ, ppm): (low field signals expected for DMAP not visible), 154.5 (s, C1,
PPh3), 133.8 (d, xJ(C,P) = 10.5, C2,6, PPh3), 131.1 (br s, C4, PPh3), 128.8 (d, xJ(C,P) = 9.6, C3,5, PPh3), 108.3
(s, C5H4N(N(CH3)2), 90.5 (d, 2J(C,P) = 3.0 Hz, C6H6), 39.1 (s, C5H4N(N(CH3)2)). 31P NMR: (121.5 MHz,
CDCl3, δ, ppm): 36.0. TGA: (Weight % decrease): 190.65–214.81 ◦C (12.58%), 214.81–263.54 ◦C(11.91%),
263.54–273.12 ◦C (3.86%), 273.12–398.48 ◦C (16.12%). UV–vis: (nm)/dichloromethane: 335.0. ESI–MS
(CH3CN): m/z 477.0, 553.0, 599.0 [M − BF4]+ (no other fragments visible).
3.3. Crystallographic Structure Determination
Crystals of X-ray diffraction quality were obtained by slow evaporation of a
dichloromethane-diethyl ether 1:1 mixture of (C2) and [(η6-C6H6)RuCl2(P(OPh)3)] at room
temperature using a vial with a narrow opening. For X-ray structure analyses the crystals are mounted
onto the tip of glass fibers, and data collection was performed with a BRUKER-AXS SMART APEX
CCD diffractometer using graphite-monochromated Mo Kα radiation (0.71073 Å) (Table 2). The data
were reduced to Fo2 and corrected for absorption effects with SAINT [43] and SADABS [44,45],
respectively. The structures were solved by direct methods and refined by full-matrix least-squares
method (SHELXL97) [46]. If not noted otherwise all non-hydrogen atoms were refined with anisotropic
displacement parameters. All hydrogen atoms were located in calculated positions to correspond to
standard bond lengths and angles. All diagrams are drawn with 30% probability thermal ellipsoids
and all hydrogen atoms were omitted for clarity. Figures of solid state molecular structures were
generated using Ortep-3 as implemented in WINGX [47] and rendered using POV-ray 3.6 [48].
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Table 2. Crystal data, details of data collection and structure refinement parameters for (C2) and
[(η6-C6H6)RuCl2{P(OPh)3}].
Complex C2 [(η6-C6H6)RuCl2{P(OPh)3}]
Empirical formula C24H21Cl4PRuSn C24H21Cl2O3PRu
Formula weight 749.94 560.35
T/K 100(2) K 446(2) K
λ/Å Crystal system 0.71073 Orthorhombic 0.71073 Orthorhombic
Space group P2(1)2(1)2(1) Pbca
a/Å 8.7164(17) 17.371(3)
b/Å 16.420(3) 14.997(3)
c/Å 18.514(4) 17.551(3)
α(deg.) 90 90
β(deg.) 90 90
γ(deg.) 90 90
V(Å3) 2649.9(9) 4572.6(14)
Z 4 8
Densitycalc(mg·m−3) 1.880 1.628
Absorption coefficient (mm−1) 2.001 1.013
F(000) 1464 2256
Crystal size (mm) 0.42 × 0.08 × 0.06 0.38 × 0.36 × 0.16
Theta range for data collection (deg.) 1.66–26.33 2.14–26.34
Limiting indices −10 ≤ h ≤ 10, −16 ≤ k ≤ 20, −23 ≤ l ≤23 −21 ≤h ≤21, −18 ≤ k ≤18, −21 ≤ l ≤ 21
Reflections Collected/Unique 17168/5368 [R(int) = 0.0409] 34691/4657 [R(int) = 0.0339]
Completeness of theta max. 26.33 (99.6%) 26.34 (99.9%)
Absorption correction SADABS SADABS
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2
Data/Restraints/Parameters 5368/0/308 4657/0/280
Goodness-of-fit on F2 (GOF) 1.042 1.117
Largest diff. peak and hole (e·Å−3) 0.805 and −0.471 0.566 and −0.404
3.4. Cell Cultures and Cytotoxicity Measurements
Human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European Collection
of Authenticated Cell Cultures (ECACC, Salisbury, UK) and non-cancerous HEK293 cells were obtained
from ATCC (Sigma, St. Gallen, Switzerland). A2780 were routinely grown in RPMI (Roswell
Park Memorial Institute) medium: 1640 GlutaMAX (Lifetechnologies, Zug, Switzerland), while
HEK293 were maintained in DMEM medium (Dulbecco's modified media), both containing 10%
heat-inactivated fetal bovine serum (FBS, Pan Biotech, Aidenbach, Germany) and 1% antibiotics
(penicillin/streptomycin), at a humidified atmosphere with 5% CO2 at 37 ◦C. Cytotoxicity was
determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide). Cells were seeded in 96-well plates as monolayers with 100 µL of cell solution per well and
were pre-incubated for 24 h in the cell culture medium. Compounds were prepared as DMSO stock
solutions that were dissolved in the culture medium and two-fold serially diluted to the appropriate
concentration to give a final DMSO concentration of maximum 0.5%. 100 µL of the compound solution
were added to each well and the plates were incubated for 72 h. Subsequently, MTT (5 mg/mL solution,
20 µL per well) was added to the cells and the plates were incubated for another 4 h. The culture
medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase
activity of vital cells were dissolved in DMSO (100 µL). The optical density, directly proportional to
the number of surviving cells, was quantified at 590 nm using a multiwell plate reader (Molecular
Devices). The fraction of surviving cells was calculated from the absorbance of untreated control
cells. The IC50 values for the inhibition of cell growth were determined by fitting the plot of the
logarithmic percentage of surviving cells against the logarithm of the drug concentration using a linear
regression function. Evaluation is based on means (±SD) from at least two independent experiments,
each comprising four tests per concentration level.
4. Conclusions
A series of novel, neutral, and cationic η6-arene ruthenium(II) complexes, some bearing one or two
trichlorostannyl groups, have been synthesized, characterized, and tested in vitro for antiproliferative
activity against human ovarian cancer cells and a non-tumorigenic cell line. Complexes C1 and C3
Inorganics 2017, 5, 44 11 of 13
exhibit rather poor cyctotoxic activity, whilst complex C2 exhibits moderate activity. The lack of
potency of complexes C1 and C3 may be linked to solubility in aqueous media, despite the presence of
stannyl ligands expected to enhance the cytotoxicity. The ionic complexes C4 and C5 are cytotoxic,
with an activity similar to cis-platin, with C4 even showing a degree of cancer cell selectivity. We are
currently attempting to further delineate the effect of the SnCl3− moiety on related complexes, taking
solubility into consideration, and will report these endeavours in due course.
Supplementary Materials: The following are available online at www.mdpi.com/2304-6740/5/3/44/s1, A PDF
document with the details of the X-ray crystallographic analysis is available. Crystallographic data (excluding
structure factors) for the structures of compounds (C2) and [(η6-C6H6)RuCl2(P(OPh)3)] reported in this paper are
deposited with the Cambridge Crystallographic Data Center as supplementary publication no. CCDC-1555463
(C2) and 1555464 ([(η6-C6H6)RuCl2(P(OPh)3)]). Copies of data can be obtained free of charge at: http://www.
ccdc.cam.ac.uk/products/csd/request/.
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